Dr Roger Flugel

KANDO id: 5320

Bio

Roger Flugel is a Principal with Sanderling Ventures and has over 15 years of experience in venture capital, consulting, and biomedical research. Dr. Flugel's investing activity at Sanderling is focused on early stage opportunities in biotechnology and pharmaceuticals, as well as medical devices and healthcare information technologies. From 2001 to 2003, Dr. Flugel served as the Director of Venture Analysis at HealthCare Ventures. While there, he worked closely with several companies on product strategy and business development. Prior to HealthCare Ventures, Dr. Flugel was a Research Associate with the MEDACorp division of Leerink Swann & Company, a boutique investment bank focused on healthcare and life sciences. At Leerink, he completed a variety of engagements in medical devices, biologics, and pharmaceuticals, for both corporate clients and institutional investors. Dr. Flugel was also an early consultant to Microbia (now Ironwood Pharmaceuticals), which went public in 2010 with a market capitalization of over $1B (NASDAQ:IRWD). He serves in a variety of roles as director, chairman, CEO, or board observer of several Sanderling portfolio companies including TheraVida, Asteres, and Xytis. He was previously involved in completing strategic corporate transactions for Kadmus (acquired by Schering-Plough, now Merck), Aderis (acquired by Schwarz Pharma, now UCB), and UltraBridge (acquired by CareCentric). Dr. Flugel received a Ph.D. in Biophysics from Harvard University, conducting his research in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. While at Harvard, he collaborated with teams from Genetics Institute (now Pfizer) and Millennium Pharmaceuticals (now Takeda) on antibiotic drug discovery. Dr. Flugel also holds a B.S. in Physics with a minor in Economics from the Massachusetts Institute of Technology.

Career


Sanderling Ventures

N/A (past)

Education